Technology | Drug-Eluting Balloons | May 03, 2018

Drug-coated In.Pact Admiral Balloon Cleared for Longer Lesions

The Medtronic In.Pact Admiral Paclitaxel-coated (DCB) Percutaneous Transluminal Angioplasty Balloon Catheter is now indicated for lesions up to 360 mm in length.

May 3, 2018 — The U.S. Food and Drug Administration (FDA) has expanded the indication for the Medtronic In.Pact Admiral Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter to include lesions up to 360 mm in length. 

This device is indicated for percutaneous transluminal angioplasty, after appropriate vessel preparation, of de novo, restenotic, or in-stent restenotic lesions with lengths up to 360 mm in superficial femoral or popliteal arteries with reference vessel diameters of 4-7 mm.

The drug-coated balloon (DCB) helps re-open blocked or narrowed arteries in the thigh and knee due to peripheral artery disease (PAD). This device can be used to prevent re-narrowing within a stent placed previously to open the blood vessel or to treat long blockages. The balloon is coated on its outer surface with the drug paclitaxel, which is an anti-proliferative drug that prevents restenosis.

"Across SFA trials, In.Pact Admiral has consistently demonstrated superior safety and efficacy compared to PTA," said Osamu Iida, M.D., Kansai Rosai Hospital, Japan, during presnetation of data on the IN.PACT Admiral SFA Japan trial in February. "We are pleased to see comparable results in Japan at two years with durable patency outcomes, low TLR and no instances of thrombosis. There has been a critical unmet need in Japan for new technologies that safely and effectively treat PAD, and we believe In.Pact Admiral is well-positioned to meet this need."

IN.PACT Admiral SFA Japan demonstrated 79.8 percent primary patency in the DCB group as compared to 46.9 percent in the PTA group at two years based on Kaplan-Meier Estimate (p<0.001). The two-year results also demonstrated a CD-TLR rate of 9.1 percent for the DCB group compared to 20.7 percent in the PTA group (p=0.177) and a freedom from CD-TLR based on Kaplan-Meier Estimate of 90.8 for the DCB group compared to 81.3 percent in the PTA group (p=0.114). In IN.PACT SFA Japan, major adverse events were also lower for the DCB at two years (15.2 percent compared to 24.1 percent in the PTA group; p=0.384), with no major target limb amputations. There were no additional safety concerns at two years.

Read the recent article "In.Pact Admiral Balloon Demonstrates Consistent, Durable Outcomes in LINC 2018 Studies."

Here is the link to the FDA approval letter.

For more information: www.medtronic.com

Related Content

News | Drug-Eluting Balloons

June 8, 2022 — The first patient has been enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK clinical trial ...

Home June 08, 2022
Home
News | Drug-Eluting Balloons

May 27, 2022 — Medtronic today announced approval from the U.S. Food and Drug Administration (FDA) for the IN.PACT 018 ...

Home May 27, 2022
Home
News | Drug-Eluting Balloons

May 27, 2022 — The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a ...

Home May 27, 2022
Home
News | Drug-Eluting Balloons

March 31, 2022 — In accordance with its commitment to patient safety, Medtronic recently voluntarily recalled a subset ...

Home March 31, 2022
Home
News | Drug-Eluting Balloons

November 10, 2021 — Biosensors International Group Ltd., a developer and manufacturer of innovative medical devices ...

Home November 10, 2021
Home
News | Drug-Eluting Balloons

October 20, 2021 — 18-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a late-breaking ...

Home October 20, 2021
Home
News | Drug-Eluting Balloons

March 12, 2021 — Philips Healthcare announced the final, five-year results of two major randomized controlled trials ...

Home March 12, 2021
Home
News | Drug-Eluting Balloons

November 3, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Boston Scientific Ranger Drug-coated ...

Home November 03, 2020
Home
News | Drug-Eluting Balloons

October 18, 2020 – The first results from the IN.PACT Below the Knee (BTK) Study, a feasibility study assessing the ...

Home October 18, 2020
Home
Videos | Drug-Eluting Balloons

Juan F. Granada, M.D., CEO of the Cardiovascular Research Foundation (CRF) worked on preclinical development work for a ...

Home September 09, 2020
Home
Subscribe Now